These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 26107422)

  • 21. [The relationship between hyperuricaemia and clinic pathology of IgA nephropathy].
    Cui MJ; Zhang BH; Xiao QF; Zhu FL; Wang HY
    Zhonghua Nei Ke Za Zhi; 2011 Aug; 50(8):659-63. PubMed ID: 22093557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study.
    Manno C; Strippoli GF; D'Altri C; Torres D; Rossini M; Schena FP
    Am J Kidney Dis; 2007 Jun; 49(6):763-75. PubMed ID: 17533019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical use of serum beta-2-microglobulin and fractional beta-2-microglobulin excretion in IgA nephropathy.
    Lai KN; Lai FM; Vallance-Owen J
    Clin Nephrol; 1986 May; 25(5):260-5. PubMed ID: 3522000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
    Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
    Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histomorphometric correlates of renal failure in IgA nephropathy.
    Vleming LJ; de Fijter JW; Westendorp RG; Daha MR; Bruijn JA; van Es LA
    Clin Nephrol; 1998 Jun; 49(6):337-44. PubMed ID: 9696428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors predicting progression of IgA nephropathies.
    Coppo R; D'Amico G
    J Nephrol; 2005; 18(5):503-12. PubMed ID: 16299675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
    McIntyre CW; Fluck RJ; Lambie SH
    Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
    Tanaka H; Suzuki K; Nakahata T; Tsugawa K; Konno Y; Tsuruga K; Ito E; Waga S
    Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
    Kanno Y; Okada H; Yamaji Y; Nakazato Y; Suzuki H
    QJM; 2005 Mar; 98(3):199-203. PubMed ID: 15728401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD44 expression in IgA nephropathy.
    Florquin S; Nunziata R; Claessen N; van den Berg FM; Pals ST; Weening JJ
    Am J Kidney Dis; 2002 Feb; 39(2):407-14. PubMed ID: 11840384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group.
    Donadio JV; Bergstralh EJ; Offord KP; Holley KE; Spencer DC
    Clin Nephrol; 1994 Feb; 41(2):65-71. PubMed ID: 8004831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregnancy and progression of IgA nephropathy: results of an Italian multicenter study.
    Limardo M; Imbasciati E; Ravani P; Surian M; Torres D; Gregorini G; Magistroni R; Casellato D; Gammaro L; Pozzi C;
    Am J Kidney Dis; 2010 Sep; 56(3):506-12. PubMed ID: 20599307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histological alterations in renal specimens as indicators of prognosis of IgA nephropathy.
    Okada H; Suzuki H; Konishi K; Sakaguchi H; Saruta T
    Clin Nephrol; 1992 May; 37(5):235-8. PubMed ID: 1606773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignant hypertension in patients with idiopathic IgA nephropathy.
    Chen Y; Tang Z; Yang G; Shen S; Yu Y; Zeng C; Chen H; Liu ZH; Li LS
    Kidney Blood Press Res; 2005; 28(4):251-8. PubMed ID: 16340218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Importance of the duration from the onset of a urinary abnormality until a biopsy is performed: a multivariate analysis on the application of renal biopsy for patients with IgA nephropathy].
    Kiyoshi Y; Hisano S; Takebayashi S
    Nihon Jinzo Gakkai Shi; 1998 Sep; 40(7):547-54. PubMed ID: 9805921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin E ameliorates renal injury in an experimental model of immunoglobulin A nephropathy.
    Trachtman H; Chan JC; Chan W; Valderrama E; Brandt R; Wakely P; Futterweit S; Maesaka J; Ma C
    Pediatr Res; 1996 Oct; 40(4):620-6. PubMed ID: 8888293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria.
    Uzu T; Harada T; Ko M; Yamato M; Takahara K; Yamauchi A
    Clin Exp Nephrol; 2003 Sep; 7(3):210-4. PubMed ID: 14586717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
    J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study.
    Wakai K; Kawamura T; Endoh M; Kojima M; Tomino Y; Tamakoshi A; Ohno Y; Inaba Y; Sakai H
    Nephrol Dial Transplant; 2006 Oct; 21(10):2800-8. PubMed ID: 16822793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial.
    Lai KN; Lai FM; Ho CP; Chan KW
    Clin Nephrol; 1986 Oct; 26(4):174-80. PubMed ID: 3536231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.